Form 4: Orchestra BioMed Director Awarded RSUs

Orchestra BioMed Holdings, Inc. Director Pamela Ann Connealy received an award of 15,000 restricted stock units.

Summary

• Pamela Ann Connealy, a Director of Orchestra BioMed Holdings, Inc. (OBIO), was awarded 15,000 shares of Common Stock in the form of Restricted Stock Units (RSUs).
• The transaction occurred on August 7, 2025, with a reported price of $0 per share, indicating an equity award rather than a cash purchase.
• Each RSU represents a contingent right to receive one share of Common Stock.
• The RSUs are scheduled to vest on the one-year anniversary of the grant date, August 7, 2025, contingent upon Ms. Connealy's continuous service to the company.
• Following this transaction, Ms. Connealy beneficially owns 48,711 shares of Common Stock.

Sentiment

Score: 7

Explanation: The sentiment is positive as the RSU award aligns director interests with shareholders, a common and beneficial practice. It is not highly impactful on its own but reflects standard corporate governance.

Positives

• The award of restricted stock units to a director aligns their interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.
• Equity compensation is a common practice for retaining and incentivizing key personnel, including directors.

Future Outlook

The 15,000 restricted stock units awarded to Director Pamela Ann Connealy are set to vest on August 7, 2026, provided her continuous service to the company.

Industry Context

The award of restricted stock units to a director is a standard form of non-cash compensation across various industries, particularly in publicly traded companies. This practice is designed to align the long-term interests of directors with those of the company's shareholders.

Comparison to Industry Standards

• Equity compensation, such as restricted stock units, is a widely adopted practice for compensating non-employee directors in U.S. public companies, including those in the biotechnology and medical device sectors like Orchestra BioMed Holdings, Inc.
• The vesting schedule of one year is common for such awards, aiming to ensure continued commitment and alignment over a reasonable period.
• The grant of 15,000 RSUs to a director is within the typical range for companies of similar market capitalization and stage of development, comparable to practices seen at companies like Inspire Medical Systems, Inc. or Shockwave Medical, Inc. for their non-executive directors.

Related Party Transactions

• Pamela Ann Connealy, a director of Orchestra BioMed Holdings, Inc., received 15,000 restricted stock units as part of her compensation.

Stakeholder Impact

• Shareholders: The RSU award aligns the director's financial interests with shareholder value creation, as the value of the compensation is directly tied to the company's stock performance.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The 15,000 restricted stock units will vest on August 7, 2026, subject to Pamela Ann Connealy's continuous service.

Key Dates

Recommendation

This Form 4 reports a routine equity award to a director, which is a common practice for aligning interests. It does not provide new information that would significantly alter the investment thesis for Orchestra BioMed Holdings, Inc., thus a 'hold' recommendation remains appropriate based solely on this filing.

Keywords

Orchestra BioMed Holdings, OBIO, SEC Form 4, Restricted Stock Units, RSU, Director Compensation, Equity Award, Insider Transaction